To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects

NCT ID: NCT07109453

Last Updated: 2025-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-25

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To Check Dermatological Safety of Test Products by 24 Hours Patch Testing

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is single center, evaluator-blinded study in healthy adult human subjects. Single 24-hour application of sponsor(s) provided test products along with positive and negative controls will be kept in contact with the skin of subjects under occlusion \|Semi occlusion \|Open patch for at least 24 hours (+ 2 hours). Study can be conducted in multiple groups. Safety will be assessed throughout the study by monitoring of adverse events. Subject's back i.e. between the scapula and waist will be utilized as application sites. Application sites will be evaluated for scoring the reaction, namely, erythema, dryness, and wrinkles on a 0-4 point scale separately for each parameter and oedema on another 0-4 points scale as per the Draize Scale after 30+5 minutes of patch removal, 24±2 hours and 168±2 hours after patch removal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Normal Sensitive Skin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Irritation Patch Test Study
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

18 Test Products along with Positive and Negative Control

1. Deep Hydration Gel
2. Anti-Wrinkle Gel
3. Anti-Aging Gel
4. Under Eye Cream
5. Brightening Cream
6. Moisturizing Cream
7. Anti-Acne Serum
8. Face Toner
9. Anti-Aging Toner
10. Clear Glow Toner
11. Super Anti-Aging Serum
12. Sun Screen SPF50
13. Anti-Pigmentation Serum
14. Super Cleansing Cream
15. Root Revive Hair Serum
16. Root Nourishment Hair Oil
17. Anti-Acne Face Wash
18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.

Group Type EXPERIMENTAL

18 Test Products along with positive and negative control

Intervention Type OTHER

1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18 Test Products along with positive and negative control

1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18-65 years (both inclusive) at the time of consent.
* Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
* Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).
* Females of childbearing potential must have a self-reported negative pregnancy test.
* Subject who do not have any previous
* history of adverse skin conditions and are not under any medication likely to interfere with the results.
* Subject is in good general health as determined by
* the Investigator on the basis of medical history.
* Subjects is willing to maintain the test patches in designated positions for 24 Hours.
* Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
* Subject must be able to understand and provide written informed consent to participate in the study.
* Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.
* For Sensitive Skin Condition Only:
* Subject scoring greater than 30 for Section 2 - Sensitive v/s Resistant skin in modified Dr Baumann's\* skin type questionnaire.
* Subject with sensitive skin as confirmed by Lactic Acid Stinging Test.

Exclusion Criteria

* Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.
* Medication which may affect skin response and/or past medical history.
* Subject having history of diabetes
* Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
* Subject suffering from any active clinically significant skin diseases which may contraindicate.
* Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.
* Participation in any patch test for irritation or sensitization within the last four weeks.
* Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).
* Use of any:
* Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
* Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted)
* Topical drugs used at application site.
* Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
* Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.
* Subject with known allergy or sensitization to medical adhesives, bandages.
* Participation in other patch study simultaneously
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Skin Harmony Lifescience Pvt. Ltd

UNKNOWN

Sponsor Role collaborator

NovoBliss Research Pvt Ltd

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Nayan Patel

Role: PRINCIPAL_INVESTIGATOR

NovoBliss Research Private Limited

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maheshvari Patel

Role: CONTACT

9909013236

Sheetal Khandwala

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NB250037-SHL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HRIPT for Collagen Dressing
NCT06283173 COMPLETED NA